Kate Goodwin is a Life Sciences Writer for BioSpace, covering a wide range of topics in the field of biotechnology and pharmaceuticals. With a focus on industry news and developments, Kate provides insightful articles on drug approvals, clinical trials, investor relations, and emerging trends in the life sciences sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Kate's coverage focuses on the healthcare and pharmaceutical industry, particularly biotechnology, pharmaceuticals, clinical trials, FDA approval processes, and investment within the sector. For effective outreach to her, consider providing data-driven insights or press releases related to groundbreaking advancements in biotech or pharmaceutical companies' developments.
As Kate's articles often cite data and rely heavily on press releases for information, she may be interested in receiving pitches that provide exclusive access to company announcements or detailed analysis of research findings from within the healthcare and pharmaceutical sectors.
Kate does not seem to have a specific geographic focus but instead covers international developments within the healthcare and pharmaceutical industries. Therefore, sources with global perspectives or those involved in cross-border collaborations could be appealing to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
We use cookies to give you a better BioSpace experience. By continuing to use our site, you are agreeing to the use of cookies as set in our Privacy Policy
We use cookies to give you a better BioSpace experience. By continuing to use our site, you are agreeing to the use of cookies as set in our Privacy Policy
By: Kate Goodwin
We use cookies to give you a better BioSpace experience. By continuing to use our site, you are agreeing to the use of cookies as set in our Privacy Policy
Pictured: Illustration of neurological health concept/iStock, Elena Nechaeva
By: Kate Goodwin
Pictured: Nasdaq headquarters in New York City/iStock, JHVEPhoto Following a Phase III victory in a late-stage major depressive disorder trial, Intra-Cellular Therapies is out to raise capital.
By: Kate Goodwin
Pictured: Man prepares his semaglutide injection pen/iStock, imyskin
Pictured: Merck headquarters in Kenilworth, NJ/iStock, JHVEPhoto
Pictured: A collage of injectable drugs, a scale and a BMI chart/Taylor Tieden for BioSpace
By: Kate Goodwin
Pictured: A sign on a J.P. Morgan building in Hong Kong/iStock, danielvfung
By: Kate Goodwin
Pictured: Regeneron headquarters in Tarrytown, N.Y./Shutterstock, Lev Radin
(833) 317-6278 
